SCHEMBL8273449

SCHEMBL8273449

Cc1nc2c(s1)CN(C(=O)[C@H](O)[C@@H](O)C(=O)NCC1CCN(c3ccccc3N)CC1C)C2

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ADAM17 P78536 13/20 0.47
▸ DPP8 Q6V1X1 2/20 0.34
▸ CHEK1 O14757 1/20 0.34
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ DPP4 P27487 2/20 0.32
▸ ADAM10 O14672 1/20 0.32
▸ MMP12 P39900 1/20 0.32
▸ MMP13 P45452 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ DPP9 Q86TI2 1/20 0.30
▸ DPP7 Q9UHL4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8217862 0.90 ADAM17 (0.60) ADAM17DPP8CHEK1ADAM10MMP12
SCHEMBL8273361 0.85 ADAM17 (0.54) ADAM17DPP8DPP4ADAM10MMP12
SCHEMBL8273441 0.85 ADAM17 (0.54) ADAM17DPP8DPP4ADAM10MMP12
SCHEMBL8273783 0.78 HDAC1 (0.43) ADAM17DPP8HDAC1HDAC2DPP4
SCHEMBL8224737 0.76 CHRM4 (0.41) ADAM17DPP8CHEK1
SCHEMBL8275634 0.75 ADAM17 (0.79) ADAM17ADAM10MMP12MMP13
SCHEMBL8217820 0.73 ADAM17 (0.70) ADAM17
SCHEMBL8217827 0.73 ADAM17 (0.70) ADAM17
SCHEMBL8275600 0.72 ADAM17 (0.45) ADAM17DPP8DPP4ADAM10MMP12
SCHEMBL8274428 0.72 ADAM17 (0.49) ADAM17HDAC1HDAC2DPP4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652020-B2 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction SCHERING CORPORATION (US) 2010-01-26 — — US disclosed
WO-2005121130-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2005-12-22 — — WO disclosed
Send feedback